Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2018

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2018


  • Products Id :- GMDHC1577TDB
  • |
  • Pages: 51
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Leptin Receptor-Pipeline Review, H2 2018'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 9 molecules.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The report 'Leptin Receptor-Pipeline Review, H2 2018' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively.

Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Oncology and Ophthalmology which include indications Obesity, Lipodystrophy, Acquired Generalized Lipodystrophy (Lawrence Syndrome), Acquired Partial Lipodystrophy (Barraquer-Simons Syndrome), Alzheimer's Disease, Breast Cancer, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome), Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)

- The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects

- The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Overview

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Companies Involved in Therapeutics Development

Jyant Technologies Inc

NeuroNano Pharma Inc

Neurotez Inc

Novelion Therapeutics Inc

Regeneron Pharmaceuticals Inc

XL-protein GmbH

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Drug Profiles

Allo-Aca-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-08-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize Leptin Receptor for Metabolic Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

memtin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metreleptin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize Leptin Receptor for Obesity-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-4461-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Dormant Products

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Discontinued Products

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)-Product Development Milestones

Featured News & Press Releases

Jun 25, 2018: Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions

Jun 01, 2018: MYALEPTA (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy

Sep 15, 2017: Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology

Jun 12, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association

May 05, 2017: Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology

Apr 04, 2017: Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society

Mar 30, 2017: Novelion Therapeutics Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society

Jan 23, 2017: Novelion Therapeutics Announces Acceptance of Marketing Authorization Application for Metreleptin by European Medicines Agency

Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy

Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease

Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin

Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin

May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy

Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy

Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer's Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Jyant Technologies Inc, H2 2018

Pipeline by NeuroNano Pharma Inc, H2 2018

Pipeline by Neurotez Inc, H2 2018

Pipeline by Novelion Therapeutics Inc, H2 2018

Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Pipeline by XL-protein GmbH, H2 2018

Dormant Projects, H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Jyant Technologies Inc

NeuroNano Pharma Inc

Neurotez Inc

Novelion Therapeutics Inc

Regeneron Pharmaceuticals Inc

XL-protein GmbH

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Therapeutic Products under Development, Key Players in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Therapeutics, Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Pipeline Overview, Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Pipeline, Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Pipeline Assessment

select a license
Single User License
USD 3500 INR 249340
Site License
USD 7000 INR 498680
Corporate User License
USD 10500 INR 748020

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com